Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares. The filing date is April 11, 2025, covering a share repurchase executed on April 10, 2025. The Company is a foreign private issuer reporting under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics and Transaction Details
The filing details a specific share buyback transaction rather than providing comprehensive financial statements (revenue, profit, or cash flow are not included in this document).
- Shares Purchased: 864,000 ordinary shares of 31½ pence each.
- Transaction Date: April 10, 2025.
- Broker: Citigroup Global Markets Limited.
- Price Range: Lowest price paid was 1,276.00 GBp; highest price paid was 1,330.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,302.33 GBp.
- Trading Venue: London Stock Exchange (XLON).
- Treasury Shares Held: Following this purchase, the Company holds 195,176,216 ordinary shares in treasury.
- Shares in Issue: 4,120,050,866 ordinary shares (excluding Treasury shares).
- Total Voting Rights: 4,120,050,866.
Material Changes and Program Status
This purchase was executed pursuant to a non-discretionary agreement entered into with the Broker on February 24, 2025. Since the inception of this agreement on February 24, 2025, the Company has purchased a total of 26,105,913 ordinary shares. The purchased shares are held as Treasury shares.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. Investors are referred to the "Risk factors" section on pages 277 to 285 of the GSK 2024 Annual Report on Form 20-F for a detailed description of these risks.
Important Facts for Investor Verification
- Verify the total number of voting rights (4,120,050,866) for compliance with Financial Conduct Authority Disclosure Guidance and Transparency Rules.
- Confirm the cumulative buyback volume of 26,105,913 shares since February 24, 2025, against the Company's authorized buyback program limits.
- Note that the transaction was executed via a non-discretionary agreement, meaning the broker acted on pre-set instructions rather than discretionary judgment.
- Review the GSK 2024 Annual Report on Form 20-F for the full list of risk factors referenced in the cautionary statement.